Hengrui Medicine: SHR-1819 Injection and SHR-1905 Injection Obtained Drug Clinical Trial Approval Letter

Hengrui Pharmaceuticals announced that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-1819 injection and SHR-1905 injection. The clinical trials will be conducted in the near future. SHR-1819 injection is a recombinant humanized monoclonal antibody targeting human IL-4R, developed independently by the company. It can simultaneously block the signal transduction of IL-4 and IL-13, and is intended for the treatment of type 2 inflammation-related diseases. SHR-1905 injection is a monoclonal antibody targeting thymic stromal lymphopoietin, which can block the release of inflammatory cytokines, inhibit the downstream signal transduction of inflammation, ultimately improve the inflammatory status, and control disease progression.